nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2C9—Capecitabine—esophageal cancer	0.164	0.665	CbGbCtD
Flecainide—CYP2C9—Cisplatin—esophageal cancer	0.0825	0.335	CbGbCtD
Flecainide—Mefloquine—CYP19A1—esophageal cancer	0.0325	0.719	CrCbGaD
Flecainide—Hemiparesis—Methotrexate—esophageal cancer	0.0166	0.0306	CcSEcCtD
Flecainide—Mefloquine—ABCB1—esophageal cancer	0.0127	0.281	CrCbGaD
Flecainide—Paresis—Methotrexate—esophageal cancer	0.00953	0.0176	CcSEcCtD
Flecainide—Balance disorder—Capecitabine—esophageal cancer	0.00855	0.0157	CcSEcCtD
Flecainide—Pulmonary fibrosis—Methotrexate—esophageal cancer	0.00791	0.0146	CcSEcCtD
Flecainide—Ageusia—Cisplatin—esophageal cancer	0.00783	0.0144	CcSEcCtD
Flecainide—Lung infiltration—Methotrexate—esophageal cancer	0.00742	0.0137	CcSEcCtD
Flecainide—Pain—Carboplatin—esophageal cancer	0.00659	0.0121	CcSEcCtD
Flecainide—Ventricular fibrillation—Capecitabine—esophageal cancer	0.0061	0.0112	CcSEcCtD
Flecainide—CYP2D6—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.0061	0.0368	CbGpPWpGaD
Flecainide—Body temperature increased—Carboplatin—esophageal cancer	0.0061	0.0112	CcSEcCtD
Flecainide—Neuropathy—Cisplatin—esophageal cancer	0.00595	0.011	CcSEcCtD
Flecainide—Ageusia—Capecitabine—esophageal cancer	0.00577	0.0106	CcSEcCtD
Flecainide—Dysphonia—Capecitabine—esophageal cancer	0.00568	0.0105	CcSEcCtD
Flecainide—Polyuria—Cisplatin—esophageal cancer	0.00524	0.00965	CcSEcCtD
Flecainide—Skin discolouration—Capecitabine—esophageal cancer	0.00517	0.00953	CcSEcCtD
Flecainide—Deafness—Cisplatin—esophageal cancer	0.00514	0.00948	CcSEcCtD
Flecainide—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00507	0.00935	CcSEcCtD
Flecainide—Interstitial lung disease—Methotrexate—esophageal cancer	0.00491	0.00905	CcSEcCtD
Flecainide—Amnesia—Cisplatin—esophageal cancer	0.0049	0.00902	CcSEcCtD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00482	0.0291	CbGpPWpGaD
Flecainide—Stupor—Methotrexate—esophageal cancer	0.00466	0.00858	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.0046	0.00848	CcSEcCtD
Flecainide—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00451	0.00831	CcSEcCtD
Flecainide—Neuropathy—Capecitabine—esophageal cancer	0.00439	0.00808	CcSEcCtD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00423	0.0255	CbGpPWpGaD
Flecainide—Urine output increased—Capecitabine—esophageal cancer	0.00423	0.00778	CcSEcCtD
Flecainide—Speech disorder—Methotrexate—esophageal cancer	0.00404	0.00745	CcSEcCtD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—SOX2—esophageal cancer	0.00401	0.0242	CbGpPWpGaD
Flecainide—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.0039	0.00718	CcSEcCtD
Flecainide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.0039	0.0235	CbGpPWpGaD
Flecainide—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00388	0.00715	CcSEcCtD
Flecainide—Sweating increased—Cisplatin—esophageal cancer	0.00387	0.00714	CcSEcCtD
Flecainide—Polyuria—Capecitabine—esophageal cancer	0.00386	0.00712	CcSEcCtD
Flecainide—Skin discolouration—Methotrexate—esophageal cancer	0.00385	0.00709	CcSEcCtD
Flecainide—Deafness—Capecitabine—esophageal cancer	0.00379	0.00698	CcSEcCtD
Flecainide—CYP2D6—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00378	0.0228	CbGpPWpGaD
Flecainide—Hepatic failure—Capecitabine—esophageal cancer	0.00377	0.00695	CcSEcCtD
Flecainide—Eye pain—Capecitabine—esophageal cancer	0.00376	0.00692	CcSEcCtD
Flecainide—CYP2C9—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00375	0.0226	CbGpPWpGaD
Flecainide—Libido decreased—Capecitabine—esophageal cancer	0.00366	0.00674	CcSEcCtD
Flecainide—Amnesia—Capecitabine—esophageal cancer	0.00361	0.00665	CcSEcCtD
Flecainide—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.0036	0.00662	CcSEcCtD
Flecainide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00355	0.0214	CbGpPWpGaD
Flecainide—Renal failure—Cisplatin—esophageal cancer	0.00349	0.00642	CcSEcCtD
Flecainide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00348	0.0064	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00339	0.00625	CcSEcCtD
Flecainide—Diplopia—Capecitabine—esophageal cancer	0.00339	0.00625	CcSEcCtD
Flecainide—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00337	0.0062	CcSEcCtD
Flecainide—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00336	0.00619	CcSEcCtD
Flecainide—Bradycardia—Cisplatin—esophageal cancer	0.00324	0.00597	CcSEcCtD
Flecainide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00324	0.0195	CbGpPWpGaD
Flecainide—Urinary retention—Capecitabine—esophageal cancer	0.00323	0.00594	CcSEcCtD
Flecainide—Cardiac arrest—Capecitabine—esophageal cancer	0.00323	0.00594	CcSEcCtD
Flecainide—Ataxia—Capecitabine—esophageal cancer	0.00319	0.00588	CcSEcCtD
Flecainide—Coma—Methotrexate—esophageal cancer	0.00318	0.00586	CcSEcCtD
Flecainide—Urine output increased—Methotrexate—esophageal cancer	0.00315	0.00579	CcSEcCtD
Flecainide—Gynaecomastia—Methotrexate—esophageal cancer	0.00311	0.00573	CcSEcCtD
Flecainide—Pulmonary oedema—Methotrexate—esophageal cancer	0.0031	0.0057	CcSEcCtD
Flecainide—Visual impairment—Cisplatin—esophageal cancer	0.00307	0.00565	CcSEcCtD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00298	0.018	CbGpPWpGaD
Flecainide—Eye disorder—Cisplatin—esophageal cancer	0.00298	0.00548	CcSEcCtD
Flecainide—Tinnitus—Cisplatin—esophageal cancer	0.00297	0.00547	CcSEcCtD
Flecainide—Flushing—Cisplatin—esophageal cancer	0.00295	0.00544	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00295	0.0178	CbGpPWpGaD
Flecainide—Bronchospasm—Capecitabine—esophageal cancer	0.00288	0.00531	CcSEcCtD
Flecainide—Polyuria—Methotrexate—esophageal cancer	0.00288	0.0053	CcSEcCtD
Flecainide—Immune system disorder—Cisplatin—esophageal cancer	0.00288	0.0053	CcSEcCtD
Flecainide—Sweating increased—Capecitabine—esophageal cancer	0.00286	0.00526	CcSEcCtD
Flecainide—Angina pectoris—Capecitabine—esophageal cancer	0.00286	0.00526	CcSEcCtD
Flecainide—Alopecia—Cisplatin—esophageal cancer	0.00281	0.00518	CcSEcCtD
Flecainide—Hepatic failure—Methotrexate—esophageal cancer	0.00281	0.00518	CcSEcCtD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.0028	0.0169	CbGpPWpGaD
Flecainide—Dysuria—Capecitabine—esophageal cancer	0.00274	0.00505	CcSEcCtD
Flecainide—Flatulence—Cisplatin—esophageal cancer	0.00273	0.00503	CcSEcCtD
Flecainide—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00268	0.00493	CcSEcCtD
Flecainide—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00268	0.00493	CcSEcCtD
Flecainide—Visual disturbance—Methotrexate—esophageal cancer	0.00266	0.00491	CcSEcCtD
Flecainide—Hyperglycaemia—Capecitabine—esophageal cancer	0.00264	0.00487	CcSEcCtD
Flecainide—Pneumonia—Capecitabine—esophageal cancer	0.00263	0.00484	CcSEcCtD
Flecainide—Vision blurred—Cisplatin—esophageal cancer	0.00261	0.00481	CcSEcCtD
Flecainide—Tremor—Cisplatin—esophageal cancer	0.0026	0.00478	CcSEcCtD
Flecainide—Ill-defined disorder—Cisplatin—esophageal cancer	0.00257	0.00474	CcSEcCtD
Flecainide—Renal failure—Capecitabine—esophageal cancer	0.00257	0.00473	CcSEcCtD
Flecainide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00256	0.00472	CcSEcCtD
Flecainide—Jaundice—Capecitabine—esophageal cancer	0.00255	0.00469	CcSEcCtD
Flecainide—Malaise—Cisplatin—esophageal cancer	0.0025	0.0046	CcSEcCtD
Flecainide—Haematuria—Capecitabine—esophageal cancer	0.00249	0.00459	CcSEcCtD
Flecainide—Leukopenia—Cisplatin—esophageal cancer	0.00248	0.00457	CcSEcCtD
Flecainide—Agranulocytosis—Capecitabine—esophageal cancer	0.00244	0.00449	CcSEcCtD
Flecainide—Convulsion—Cisplatin—esophageal cancer	0.0024	0.00442	CcSEcCtD
Flecainide—Bradycardia—Capecitabine—esophageal cancer	0.00239	0.0044	CcSEcCtD
Flecainide—Ataxia—Methotrexate—esophageal cancer	0.00237	0.00437	CcSEcCtD
Flecainide—Myalgia—Cisplatin—esophageal cancer	0.00236	0.00435	CcSEcCtD
Flecainide—Anxiety—Cisplatin—esophageal cancer	0.00235	0.00433	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00234	0.00432	CcSEcCtD
Flecainide—CYP2D6—Xenobiotics—CYP2A6—esophageal cancer	0.00234	0.0141	CbGpPWpGaD
Flecainide—Hypoaesthesia—Capecitabine—esophageal cancer	0.00233	0.0043	CcSEcCtD
Flecainide—Discomfort—Cisplatin—esophageal cancer	0.00233	0.00429	CcSEcCtD
Flecainide—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.00232	0.014	CbGpPWpGaD
Flecainide—Oedema—Cisplatin—esophageal cancer	0.00226	0.00417	CcSEcCtD
Flecainide—Visual impairment—Capecitabine—esophageal cancer	0.00226	0.00417	CcSEcCtD
Flecainide—CYP2D6—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00225	0.0136	CbGpPWpGaD
Flecainide—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00223	0.0135	CbGpPWpGaD
Flecainide—Nervous system disorder—Cisplatin—esophageal cancer	0.00222	0.00409	CcSEcCtD
Flecainide—Thrombocytopenia—Cisplatin—esophageal cancer	0.00221	0.00408	CcSEcCtD
Flecainide—Tachycardia—Cisplatin—esophageal cancer	0.00221	0.00407	CcSEcCtD
Flecainide—Skin disorder—Cisplatin—esophageal cancer	0.0022	0.00405	CcSEcCtD
Flecainide—Eye disorder—Capecitabine—esophageal cancer	0.00219	0.00404	CcSEcCtD
Flecainide—Tinnitus—Capecitabine—esophageal cancer	0.00219	0.00403	CcSEcCtD
Flecainide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00219	0.00403	CcSEcCtD
Flecainide—Flushing—Capecitabine—esophageal cancer	0.00218	0.00401	CcSEcCtD
Flecainide—Anorexia—Cisplatin—esophageal cancer	0.00216	0.00397	CcSEcCtD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00213	0.0129	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00213	0.0129	CbGpPWpGaD
Flecainide—Immune system disorder—Capecitabine—esophageal cancer	0.00212	0.0039	CcSEcCtD
Flecainide—Hypotension—Cisplatin—esophageal cancer	0.00211	0.00389	CcSEcCtD
Flecainide—Alopecia—Capecitabine—esophageal cancer	0.00207	0.00382	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00206	0.0038	CcSEcCtD
Flecainide—Dysuria—Methotrexate—esophageal cancer	0.00204	0.00376	CcSEcCtD
Flecainide—Paraesthesia—Cisplatin—esophageal cancer	0.00203	0.00374	CcSEcCtD
Flecainide—Dyspnoea—Cisplatin—esophageal cancer	0.00202	0.00371	CcSEcCtD
Flecainide—Flatulence—Capecitabine—esophageal cancer	0.00201	0.00371	CcSEcCtD
Flecainide—Erectile dysfunction—Methotrexate—esophageal cancer	0.00201	0.0037	CcSEcCtD
Flecainide—Dysgeusia—Capecitabine—esophageal cancer	0.002	0.00368	CcSEcCtD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.002	0.012	CbGpPWpGaD
Flecainide—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00199	0.00367	CcSEcCtD
Flecainide—Decreased appetite—Cisplatin—esophageal cancer	0.00197	0.00362	CcSEcCtD
Flecainide—Pneumonia—Methotrexate—esophageal cancer	0.00196	0.00361	CcSEcCtD
Flecainide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00195	0.0036	CcSEcCtD
Flecainide—Pain—Cisplatin—esophageal cancer	0.00193	0.00356	CcSEcCtD
Flecainide—Vision blurred—Capecitabine—esophageal cancer	0.00193	0.00355	CcSEcCtD
Flecainide—Tremor—Capecitabine—esophageal cancer	0.00191	0.00353	CcSEcCtD
Flecainide—Renal failure—Methotrexate—esophageal cancer	0.00191	0.00352	CcSEcCtD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0019	0.0115	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.0019	0.0114	CbGpPWpGaD
Flecainide—Ill-defined disorder—Capecitabine—esophageal cancer	0.0019	0.00349	CcSEcCtD
Flecainide—Feeling abnormal—Cisplatin—esophageal cancer	0.00186	0.00343	CcSEcCtD
Flecainide—Haematuria—Methotrexate—esophageal cancer	0.00186	0.00342	CcSEcCtD
Flecainide—Malaise—Capecitabine—esophageal cancer	0.00184	0.00339	CcSEcCtD
Flecainide—Vertigo—Capecitabine—esophageal cancer	0.00184	0.00338	CcSEcCtD
Flecainide—Syncope—Capecitabine—esophageal cancer	0.00183	0.00337	CcSEcCtD
Flecainide—Leukopenia—Capecitabine—esophageal cancer	0.00183	0.00337	CcSEcCtD
Flecainide—CYP2D6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00182	0.011	CbGpPWpGaD
Flecainide—Agranulocytosis—Methotrexate—esophageal cancer	0.00182	0.00335	CcSEcCtD
Flecainide—Palpitations—Capecitabine—esophageal cancer	0.00181	0.00333	CcSEcCtD
Flecainide—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.0018	0.0109	CbGpPWpGaD
Flecainide—Loss of consciousness—Capecitabine—esophageal cancer	0.0018	0.00331	CcSEcCtD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—KDR—esophageal cancer	0.00179	0.0108	CbGpPWpGaD
Flecainide—Body temperature increased—Cisplatin—esophageal cancer	0.00179	0.00329	CcSEcCtD
Flecainide—Cough—Capecitabine—esophageal cancer	0.00178	0.00328	CcSEcCtD
Flecainide—SCN4A—Axon guidance—PFN1—esophageal cancer	0.00178	0.0107	CbGpPWpGaD
Flecainide—Hypertension—Capecitabine—esophageal cancer	0.00176	0.00325	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00175	0.0106	CbGpPWpGaD
Flecainide—Myalgia—Capecitabine—esophageal cancer	0.00174	0.0032	CcSEcCtD
Flecainide—Arthralgia—Capecitabine—esophageal cancer	0.00174	0.0032	CcSEcCtD
Flecainide—Chest pain—Capecitabine—esophageal cancer	0.00174	0.0032	CcSEcCtD
Flecainide—Anxiety—Capecitabine—esophageal cancer	0.00173	0.00319	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00173	0.00318	CcSEcCtD
Flecainide—Discomfort—Capecitabine—esophageal cancer	0.00172	0.00317	CcSEcCtD
Flecainide—Dry mouth—Capecitabine—esophageal cancer	0.0017	0.00313	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00169	0.0102	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—NOTCH1—esophageal cancer	0.00169	0.0102	CbGpPWpGaD
Flecainide—Visual impairment—Methotrexate—esophageal cancer	0.00168	0.0031	CcSEcCtD
Flecainide—Confusional state—Capecitabine—esophageal cancer	0.00168	0.0031	CcSEcCtD
Flecainide—Oedema—Capecitabine—esophageal cancer	0.00167	0.00307	CcSEcCtD
Flecainide—Shock—Capecitabine—esophageal cancer	0.00164	0.00302	CcSEcCtD
Flecainide—Nervous system disorder—Capecitabine—esophageal cancer	0.00164	0.00301	CcSEcCtD
Flecainide—Eye disorder—Methotrexate—esophageal cancer	0.00163	0.00301	CcSEcCtD
Flecainide—Thrombocytopenia—Capecitabine—esophageal cancer	0.00163	0.00301	CcSEcCtD
Flecainide—Tinnitus—Methotrexate—esophageal cancer	0.00163	0.003	CcSEcCtD
Flecainide—Tachycardia—Capecitabine—esophageal cancer	0.00163	0.003	CcSEcCtD
Flecainide—Asthenia—Cisplatin—esophageal cancer	0.00162	0.00299	CcSEcCtD
Flecainide—Skin disorder—Capecitabine—esophageal cancer	0.00162	0.00298	CcSEcCtD
Flecainide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00161	0.00297	CcSEcCtD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00159	0.00962	CbGpPWpGaD
Flecainide—Anorexia—Capecitabine—esophageal cancer	0.00159	0.00293	CcSEcCtD
Flecainide—Immune system disorder—Methotrexate—esophageal cancer	0.00158	0.00291	CcSEcCtD
Flecainide—Hypotension—Capecitabine—esophageal cancer	0.00156	0.00287	CcSEcCtD
Flecainide—Diarrhoea—Cisplatin—esophageal cancer	0.00155	0.00285	CcSEcCtD
Flecainide—Alopecia—Methotrexate—esophageal cancer	0.00154	0.00284	CcSEcCtD
Flecainide—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00153	0.00921	CbGpPWpGaD
Flecainide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00152	0.0028	CcSEcCtD
Flecainide—Insomnia—Capecitabine—esophageal cancer	0.00151	0.00278	CcSEcCtD
Flecainide—Paraesthesia—Capecitabine—esophageal cancer	0.0015	0.00276	CcSEcCtD
Flecainide—Dysgeusia—Methotrexate—esophageal cancer	0.00149	0.00274	CcSEcCtD
Flecainide—Dyspnoea—Capecitabine—esophageal cancer	0.00149	0.00274	CcSEcCtD
Flecainide—Dyspepsia—Capecitabine—esophageal cancer	0.00147	0.0027	CcSEcCtD
Flecainide—Decreased appetite—Capecitabine—esophageal cancer	0.00145	0.00267	CcSEcCtD
Flecainide—SCN4A—Axon guidance—CFL1—esophageal cancer	0.00144	0.00869	CbGpPWpGaD
Flecainide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00144	0.00265	CcSEcCtD
Flecainide—Vomiting—Cisplatin—esophageal cancer	0.00144	0.00265	CcSEcCtD
Flecainide—Fatigue—Capecitabine—esophageal cancer	0.00144	0.00265	CcSEcCtD
Flecainide—Vision blurred—Methotrexate—esophageal cancer	0.00143	0.00264	CcSEcCtD
Flecainide—Rash—Cisplatin—esophageal cancer	0.00143	0.00263	CcSEcCtD
Flecainide—Constipation—Capecitabine—esophageal cancer	0.00143	0.00263	CcSEcCtD
Flecainide—Pain—Capecitabine—esophageal cancer	0.00143	0.00263	CcSEcCtD
Flecainide—Dermatitis—Cisplatin—esophageal cancer	0.00142	0.00262	CcSEcCtD
Flecainide—Ill-defined disorder—Methotrexate—esophageal cancer	0.00141	0.0026	CcSEcCtD
Flecainide—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.0014	0.00846	CbGpPWpGaD
Flecainide—Feeling abnormal—Capecitabine—esophageal cancer	0.00137	0.00253	CcSEcCtD
Flecainide—Malaise—Methotrexate—esophageal cancer	0.00137	0.00253	CcSEcCtD
Flecainide—Vertigo—Methotrexate—esophageal cancer	0.00137	0.00252	CcSEcCtD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00137	0.00824	CbGpPWpGaD
Flecainide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00136	0.00251	CcSEcCtD
Flecainide—Leukopenia—Methotrexate—esophageal cancer	0.00136	0.00251	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00136	0.00819	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00135	0.00817	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00135	0.00813	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00135	0.00812	CbGpPWpGaD
Flecainide—Nausea—Cisplatin—esophageal cancer	0.00134	0.00247	CcSEcCtD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00134	0.00806	CbGpPWpGaD
Flecainide—Cough—Methotrexate—esophageal cancer	0.00133	0.00244	CcSEcCtD
Flecainide—Urticaria—Capecitabine—esophageal cancer	0.00132	0.00244	CcSEcCtD
Flecainide—Body temperature increased—Capecitabine—esophageal cancer	0.00132	0.00243	CcSEcCtD
Flecainide—Abdominal pain—Capecitabine—esophageal cancer	0.00132	0.00243	CcSEcCtD
Flecainide—Convulsion—Methotrexate—esophageal cancer	0.00132	0.00243	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00132	0.00794	CbGpPWpGaD
Flecainide—Arthralgia—Methotrexate—esophageal cancer	0.00129	0.00238	CcSEcCtD
Flecainide—Myalgia—Methotrexate—esophageal cancer	0.00129	0.00238	CcSEcCtD
Flecainide—Chest pain—Methotrexate—esophageal cancer	0.00129	0.00238	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00129	0.00237	CcSEcCtD
Flecainide—Discomfort—Methotrexate—esophageal cancer	0.00128	0.00236	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—PFN1—esophageal cancer	0.00127	0.00765	CbGpPWpGaD
Flecainide—Confusional state—Methotrexate—esophageal cancer	0.00125	0.00231	CcSEcCtD
Flecainide—SCN4A—Axon guidance—ACTB—esophageal cancer	0.00122	0.00739	CbGpPWpGaD
Flecainide—Nervous system disorder—Methotrexate—esophageal cancer	0.00122	0.00224	CcSEcCtD
Flecainide—Thrombocytopenia—Methotrexate—esophageal cancer	0.00122	0.00224	CcSEcCtD
Flecainide—Skin disorder—Methotrexate—esophageal cancer	0.00121	0.00222	CcSEcCtD
Flecainide—SCN5A—Axon guidance—PFN1—esophageal cancer	0.0012	0.00727	CbGpPWpGaD
Flecainide—Hyperhidrosis—Methotrexate—esophageal cancer	0.0012	0.00221	CcSEcCtD
Flecainide—Asthenia—Capecitabine—esophageal cancer	0.0012	0.0022	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00119	0.00718	CbGpPWpGaD
Flecainide—Anorexia—Methotrexate—esophageal cancer	0.00118	0.00218	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00118	0.00712	CbGpPWpGaD
Flecainide—Pruritus—Capecitabine—esophageal cancer	0.00118	0.00217	CcSEcCtD
Flecainide—Hypotension—Methotrexate—esophageal cancer	0.00116	0.00214	CcSEcCtD
Flecainide—Diarrhoea—Capecitabine—esophageal cancer	0.00114	0.0021	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00113	0.00208	CcSEcCtD
Flecainide—Insomnia—Methotrexate—esophageal cancer	0.00112	0.00207	CcSEcCtD
Flecainide—Paraesthesia—Methotrexate—esophageal cancer	0.00111	0.00205	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00111	0.00668	CbGpPWpGaD
Flecainide—Dyspnoea—Methotrexate—esophageal cancer	0.00111	0.00204	CcSEcCtD
Flecainide—Somnolence—Methotrexate—esophageal cancer	0.0011	0.00203	CcSEcCtD
Flecainide—Dizziness—Capecitabine—esophageal cancer	0.0011	0.00203	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.0011	0.00662	CbGpPWpGaD
Flecainide—Dyspepsia—Methotrexate—esophageal cancer	0.00109	0.00201	CcSEcCtD
Flecainide—Decreased appetite—Methotrexate—esophageal cancer	0.00108	0.00199	CcSEcCtD
Flecainide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00107	0.00197	CcSEcCtD
Flecainide—Fatigue—Methotrexate—esophageal cancer	0.00107	0.00197	CcSEcCtD
Flecainide—Pain—Methotrexate—esophageal cancer	0.00106	0.00195	CcSEcCtD
Flecainide—Vomiting—Capecitabine—esophageal cancer	0.00106	0.00195	CcSEcCtD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00106	0.00639	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00106	0.00638	CbGpPWpGaD
Flecainide—Rash—Capecitabine—esophageal cancer	0.00105	0.00194	CcSEcCtD
Flecainide—Dermatitis—Capecitabine—esophageal cancer	0.00105	0.00193	CcSEcCtD
Flecainide—Headache—Capecitabine—esophageal cancer	0.00104	0.00192	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—CFL1—esophageal cancer	0.00103	0.0062	CbGpPWpGaD
Flecainide—Feeling abnormal—Methotrexate—esophageal cancer	0.00102	0.00188	CcSEcCtD
Flecainide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00101	0.00187	CcSEcCtD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00101	0.00608	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—SOX2—esophageal cancer	0.000992	0.00599	CbGpPWpGaD
Flecainide—Nausea—Capecitabine—esophageal cancer	0.00099	0.00182	CcSEcCtD
Flecainide—Urticaria—Methotrexate—esophageal cancer	0.000986	0.00182	CcSEcCtD
Flecainide—Body temperature increased—Methotrexate—esophageal cancer	0.000981	0.00181	CcSEcCtD
Flecainide—Abdominal pain—Methotrexate—esophageal cancer	0.000981	0.00181	CcSEcCtD
Flecainide—SCN5A—Axon guidance—CFL1—esophageal cancer	0.000976	0.00589	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000973	0.00587	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000965	0.00582	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00096	0.00579	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000952	0.00574	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.0009	0.00543	CbGpPWpGaD
Flecainide—Asthenia—Methotrexate—esophageal cancer	0.00089	0.00164	CcSEcCtD
Flecainide—Pruritus—Methotrexate—esophageal cancer	0.000878	0.00162	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—ACTB—esophageal cancer	0.000874	0.00527	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—PFN1—esophageal cancer	0.00086	0.00519	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CTNNA1—esophageal cancer	0.000858	0.00518	CbGpPWpGaD
Flecainide—Diarrhoea—Methotrexate—esophageal cancer	0.000849	0.00156	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000839	0.00506	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000832	0.00502	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ACTB—esophageal cancer	0.00083	0.00501	CbGpPWpGaD
Flecainide—Dizziness—Methotrexate—esophageal cancer	0.000821	0.00151	CcSEcCtD
Flecainide—SCN4A—Axon guidance—ABL1—esophageal cancer	0.00082	0.00494	CbGpPWpGaD
Flecainide—SCN4A—L1CAM interactions—EGFR—esophageal cancer	0.000815	0.00492	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00079	0.00477	CbGpPWpGaD
Flecainide—Vomiting—Methotrexate—esophageal cancer	0.000789	0.00145	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000789	0.00476	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000784	0.00473	CbGpPWpGaD
Flecainide—Rash—Methotrexate—esophageal cancer	0.000783	0.00144	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000782	0.00472	CbGpPWpGaD
Flecainide—Dermatitis—Methotrexate—esophageal cancer	0.000782	0.00144	CcSEcCtD
Flecainide—Headache—Methotrexate—esophageal cancer	0.000778	0.00143	CcSEcCtD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000777	0.00469	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000774	0.00467	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000767	0.00463	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000748	0.00451	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000741	0.00447	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000737	0.00445	CbGpPWpGaD
Flecainide—Nausea—Methotrexate—esophageal cancer	0.000737	0.00136	CcSEcCtD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000731	0.00441	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000728	0.00439	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000721	0.00435	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.000721	0.00435	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.000715	0.00431	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CFL1—esophageal cancer	0.000697	0.0042	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—SOX2—esophageal cancer	0.000673	0.00406	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000645	0.00389	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000636	0.00384	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.000633	0.00382	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00063	0.0038	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000627	0.00378	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KDR—esophageal cancer	0.000621	0.00375	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MET—esophageal cancer	0.000608	0.00367	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000598	0.00361	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000593	0.00357	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ACTB—esophageal cancer	0.000592	0.00357	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.000588	0.00355	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—ABL1—esophageal cancer	0.000585	0.00353	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000583	0.00352	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CTNNA1—esophageal cancer	0.000582	0.00351	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00058	0.0035	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000575	0.00347	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—SMAD4—esophageal cancer	0.000566	0.00342	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ABL1—esophageal cancer	0.000556	0.00335	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—EGFR—esophageal cancer	0.000552	0.00333	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000547	0.0033	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000542	0.00327	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000539	0.00325	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000534	0.00322	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000446	0.00269	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—ERBB2—esophageal cancer	0.000444	0.00268	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KDR—esophageal cancer	0.000443	0.00267	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000442	0.00266	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00044	0.00265	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MET—esophageal cancer	0.000434	0.00262	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000424	0.00256	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KDR—esophageal cancer	0.000421	0.00254	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.00042	0.00253	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000419	0.00253	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—NOTCH1—esophageal cancer	0.000418	0.00252	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000415	0.00251	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MET—esophageal cancer	0.000412	0.00249	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000405	0.00245	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000397	0.0024	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ABL1—esophageal cancer	0.000396	0.00239	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000394	0.00238	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—SMAD4—esophageal cancer	0.000384	0.00232	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CREBBP—esophageal cancer	0.000379	0.00228	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000338	0.00204	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000335	0.00202	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000333	0.00201	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00033	0.00199	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000323	0.00195	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000318	0.00192	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—ERBB2—esophageal cancer	0.000317	0.00191	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000315	0.0019	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000313	0.00189	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00031	0.00187	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—EGFR—esophageal cancer	0.000308	0.00186	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ERBB2—esophageal cancer	0.000301	0.00182	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KDR—esophageal cancer	0.0003	0.00181	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MET—esophageal cancer	0.000294	0.00177	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—NOTCH1—esophageal cancer	0.000283	0.00171	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EP300—esophageal cancer	0.000258	0.00156	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CREBBP—esophageal cancer	0.000257	0.00155	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EGFR—esophageal cancer	0.00022	0.00133	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000218	0.00132	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ERBB2—esophageal cancer	0.000215	0.0013	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—EGFR—esophageal cancer	0.000209	0.00126	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.00019	0.00115	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EP300—esophageal cancer	0.000175	0.00105	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000171	0.00103	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000171	0.00103	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000169	0.00102	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000169	0.00102	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000151	0.000912	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EGFR—esophageal cancer	0.000149	0.000899	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CA1—esophageal cancer	0.000145	0.000875	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000145	0.000875	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CA1—esophageal cancer	0.000144	0.000868	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000144	0.000868	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CA2—esophageal cancer	0.000133	0.0008	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CA2—esophageal cancer	0.000132	0.000793	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000129	0.000776	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000123	0.000744	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000123	0.000744	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000122	0.000738	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000122	0.000738	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000121	0.000729	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000108	0.000652	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000107	0.000647	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000103	0.000624	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000102	0.000618	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000101	0.000607	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP26A1—esophageal cancer	9.97e-05	0.000601	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALOX15—esophageal cancer	9.8e-05	0.000591	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALOX15—esophageal cancer	9.71e-05	0.000586	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TPI1—esophageal cancer	9.35e-05	0.000564	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTO1—esophageal cancer	9.35e-05	0.000564	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TPI1—esophageal cancer	9.27e-05	0.000559	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTO1—esophageal cancer	9.27e-05	0.000559	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALDOB—esophageal cancer	8.96e-05	0.000541	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALDOB—esophageal cancer	8.89e-05	0.000536	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GAPDH—esophageal cancer	8.63e-05	0.00052	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GAPDH—esophageal cancer	8.55e-05	0.000516	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CRABP1—esophageal cancer	8.55e-05	0.000516	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CRABP1—esophageal cancer	8.48e-05	0.000511	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GNG7—esophageal cancer	8.13e-05	0.000491	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GNG7—esophageal cancer	8.06e-05	0.000486	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALDH2—esophageal cancer	7.62e-05	0.00046	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALDH2—esophageal cancer	7.56e-05	0.000456	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.25e-05	0.000437	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTT1—esophageal cancer	7.19e-05	0.000433	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.17e-05	0.000432	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP2A6—esophageal cancer	7.1e-05	0.000428	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.08e-05	0.000427	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTGS1—esophageal cancer	6.79e-05	0.00041	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ENO1—esophageal cancer	6.79e-05	0.00041	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTGS1—esophageal cancer	6.73e-05	0.000406	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ENO1—esophageal cancer	6.73e-05	0.000406	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PSME1—esophageal cancer	6.69e-05	0.000404	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PSME2—esophageal cancer	6.69e-05	0.000404	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PSME2—esophageal cancer	6.64e-05	0.0004	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PSME1—esophageal cancer	6.64e-05	0.0004	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.79e-05	0.00035	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP1B1—esophageal cancer	5.78e-05	0.000348	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP1B1—esophageal cancer	5.73e-05	0.000345	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.43e-05	0.000328	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP19A1—esophageal cancer	5.38e-05	0.000325	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HMOX1—esophageal cancer	4.96e-05	0.000299	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HMOX1—esophageal cancer	4.91e-05	0.000296	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.82e-05	0.000291	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCB1—esophageal cancer	4.76e-05	0.000287	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCB1—esophageal cancer	4.72e-05	0.000284	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.56e-05	0.000215	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.18e-05	0.000192	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.15e-05	0.00019	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NOS3—esophageal cancer	2.85e-05	0.000172	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NOS3—esophageal cancer	2.82e-05	0.00017	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.6e-05	0.000157	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.58e-05	0.000156	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—EP300—esophageal cancer	2.16e-05	0.000131	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—EP300—esophageal cancer	2.15e-05	0.000129	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.6e-05	9.66e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.59e-05	9.58e-05	CbGpPWpGaD
